


CONTENTS

	Page
Acknowledgement	d
Abstract in Thai	e
Abstract in English	g
List of Tables	k
List of Figures	m
List of Abbreviations	o
Chapter 1 Introduction	1
1.1 Allergic rhinitis (AR)	2
1.2 Background of medication	10
1.3 Shallot	11
1.4 Rhinomanometry (RMM)	14
1.5 Nasal cytology	16
1.6 Objectives of the study	18
Chapter 2 Materials and methods	19
2.1 Study design	19
2.2 Patients selection	19
2.3 Drug and chemical substances	21
2.4 Protocol outline	22
2.5 Efficacy assessments	25
2.6 Safety assessments	29
2.7 Statistical analysis	29

Chapter 3 Results	30
3.1 Patients Characteristics	30
3.2 Skin prick test	33
3.3 Subjective assessments	34
3.4 Objective assessments	55
3.5 Safety assessments	58
Chapter 4 Discussion	62
Chapter 5 Conclusions	68
References	69
Appendix	80
Curriculum Vitae	84



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF TABLES

	Page
Table 3.1 Demographic data	31
Table 3.2 Baseline data of all subjects in the study	32
Table 3.3 Numbers of patients with positive skin prick test	34
Table 3.4 TNSS and nasal symptoms at week 0, 1, 2, 3, and 4 in both groups	36
Table 3.5 Percent mean changes from week 0 in TNSS and nasal symptoms at week 1, 2, 3, and 4 in both groups	39
Table 3.6 TOSS and ocular symptoms at week 0, 1, 2, 3, and 4 in both groups	44
Table 3.7 Percent mean changes from week 0 in TOSS and ocular symptoms at week 1, 2, 3, and 4 in both groups	47
Table 3.8 Mean VAS at week 0, 2, and 4 in both groups	50
Table 3.9 Percent mean changes from week 0 in VAS at week 2 and 4 in both groups	50
Table 3.10 The number of 50% responder rate of VAS improvement after treatment for 2 and 4 weeks	51
Table 3.11 Mean of subjects' satisfactory score (%) after treatment for 4 weeks in both groups	51
Table 3.12 Mean score of Rhinoconjunctivitis Quality of life questionnaire (Rcq-36) at week 0 and 4 in both groups	53
Table 3.13 Mean changes from week 0 in scores of the Rhinoconjunctivitis Quality of life questionnaire (Rcq-36) in both groups	54
Table 3.14 Mean NAR at week 0 and 4 in both groups	55
Table 3.15 Mean number of cells from nasal cytology at week 2 and 4 in both groups	56

Table 3.16	Mean changes from week 0 in cells from nasal cytology at week 0, 2, and 4 in both groups	57
Table 3.17	AEs that occurred during the study in both groups	58
Table 3.18	Vital signs at week 0 and 4 in both groups	60
Table 3.19	Laboratory at week 0 and 4 in both groups	60
Table 3.20	Percent mean changes from week 0 in laboratory for safety assessment in both groups	61



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
 Copyright© by Chiang Mai University
 All rights reserved

LIST OF FIGURES

		Page
Figure 1.1	Classification of AR according to ARIA guideline	3
Figure 1.2	Algorithm for AR management according to ARIA guideline	9
Figure 1.3	Chemical structure of cetirizine	11
Figure 1.4	Shallot or <i>Allium ascalonicum</i> L.	12
Figure 1.5	Diagrammatic of RMM recording of transnasal pressure against flow during breathing at rest through an unremarkable nose and through an obstructed nose	15
Figure 1.6	Rhinomanometer	15
Figure 2.1	Calculation of number of subjects from G*power program	20
Figure 2.2	Diagram of the protocol procedure of the study	23
Figure 2.3	Visual analog scale for overall symptom score	26
Figure 2.4	Satisfactory scale for subjects' satisfactory score (%)	26
Figure 2.5	Various size of nasal adapter for anterior rhinomanometry procedure	27
Figure 2.6	Position for anterior rhinomanometry procedure	28
Figure 2.7	Anterior rhinomanometer (PC 300, ATMOS, Germany)	28
Figure 3.1	Flow chart of patients during the study	31
Figure 3.2	TNSS at week 0, 1, 2, 3, and 4 in both groups	37
Figure 3.3	Itchy nose at week 0, 1, 2, 3, and 4 in both groups	37
Figure 3.4	Nasal obstruction at week 0, 1, 2, 3, and 4 in both groups	38
Figure 3.5	Sneezing at week 0, 1, 2, 3, and 4 in both groups	38
Figure 3.6	Rhinorrhea at week 0, 1, 2, 3, and 4 in both groups	39
Figure 3.7	50% responder rate of itchy nose after treatment	40
Figure 3.8	50% responder rate of nasal obstruction after treatment	41
Figure 3.9	50% responder rate of sneezing after treatment	41
Figure 3.10	50% responder rate of rhinorrhea after treatment	42

Figure 3.11	TOSS at week 0, 1, 2, 3, and 4 in both groups	45
Figure 3.12	Itchy eyes at week 0, 1, 2, 3, and 4 in both groups	45
Figure 3.13	Watery eyes at week 0, 1, 2, 3, and 4 in both groups	46
Figure 3.14	Eye redness at week 0, 1, 2, 3, and 4 in both groups	46
Figure 3.15	50% responder rate of itchy eyes after treatment	48
Figure 3.16	50% responder rate of watery eyes after treatment	48
Figure 3.17	50% responder rate of eye redness after treatment	49
Figure 3.18	VAS at week 0, 2, 4 in both groups	50
Figure 3.19	50% responder rate of VAS improvement after treatment for 2 and 4 weeks	51
Figure 3.20	NAR at 75 Pa/cm ³ /s at week 0 and 4	55

LIST OF ABBREVIATIONS

AEs	Adverse events
ALT	Alanine aminotransferase
APCs	Antigen presenting cells
AR	Allergic rhinitis
ARIA	Allergic Rhinitis with its Impact on Asthma
AST	Aspartate aminotransferase
BMI	Body mass index
BUN	Blood urea nitrogen
CAMs	Complementary and alternative medicines
CBC	Completed blood count
cm	Centimeter
CNS	Central nervous system
Cr	Creatinine
eGFR	Estimated glomerular filtration rate
FDA	Food and Drug Administration
g	Gram
GI	Gastrointestinal
Hb	Hemoglobin
Hct	Hematocrit
h.s.	Hora somni (at bedtime)
IgE	Immunoglobulin E
IL	Interleukin
kg	Kilogram
L	Liter
LTRAs	Leukotriene receptor antagonists
m	Meter
mg	Milligram

MHC	Major histocompatibility complex
min	Minute
mL	Milliliter
mm	Millimeter
mmHg	Millimeter of mercury
NAR	Nasal airway resistance
OD	Ommi die (once daily)
Pa	Pascal
PC	Post cibum (after meal)
Plt	Platelets
PO	Per oral
QOL	Quality of life
Rcq	Rhinoconjunctivitis Quality of Life Questionnaire
RMM	Rhinomanometry
s	Second
SAEs	Serious adverse events
SD	Standard deviation
SPSS	Statistical Package for the Social Sciences
Th	T-helper
tid	Ter in die (three times per day)
TNSS	Total nasal symptom score
TOSS	Total ocular symptom score
US	United States
VAS	Visual analog scores
V/W	Volume per weight
WBC	White blood cell
μmol	Micromolar